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Vasculitis is a rare complication of antithyroid drugs (ATDs). It was ﬁrst described with Propylthiouracil (PTU). We report a new
case of antineutrophil cytoplasmic antibody (ANCA) vasculitis with glomerulonephritis induced by Benzylthiouracile (BTU). A
50-year-old man with Graves disease treated with BTU developed general malaise and haematuria without skin rash or respiratory
involvement. Laboratory data revealed acute renal failure with proteinuria and haematuria. An indirect immunoﬂuorescence test
for ANCA was positive, showing a perinuclear pattern with speciﬁcity antimyeloperoxidase (MPO). A renal biopsy was performed
and revealed pauci-immune extracapillary glomerular nephropathy and necrotic vasculitis lesions. Based on these ﬁndings we
concluded to the diagnosis of rapidly progressive glomerulonephritis associated with ANCA induced by BTU therapy. The drug
was therefore discontinued and the patient was treated with steroids and immunosuppressive treatment during 3 months. Renal
failure,proteinuriaandhaematuriasigniﬁcantlyimprovedwithin2months.However,P-ANCAremainedpositiveuntil10months
after drug withdrawal. Thyroid function was kept within normal range using iodine solution. We demonstrated clearly that BTU
may induce severe forms of vasculitis with glomerulonephritis. Thus, the ANCA must be measured when confronted to systemic
manifestation during treatment.
Copyright © 2009 Sihem Trimeche Ajmi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Antithyroid drugs (ATDs) such as Propylthiouracil (PTU)
and Benzylthiouracil (BTU) are widely used for treatment
of Graves disease. Commonly adverse eﬀects related to the
use of antithyroid drugs include agranulocytosis, cutaneous
macular or papular skin rash, toxic hepatitis and induced
lupus-like syndrome [1, 2]. ANCA positive vasculitis is a rare
and severe complication of this treatment, described ﬁrstly
with PTU [3], than with other ATD such as Carbimazole,
Methimazole and recently Benzylthiouracil [4]. We report
here a new case of Benzylthiouracil-induced ANCA positive
vasculitis resulting in a necrotizing or crescentic glomeru-
lonephritis.
2.CaseReport
A 50-year-old man was admitted to the hospital because of
general malaise and haematuria. He has a history of Graves
disease diagnosed in 2004 and treated with Benzylthiouracile
(Basd` ene) 300mg/d for 8 months. On admission, his blood
pressure was 120/70mmHg and his pulse was regular
at 108/min with no fever. On physical examination, the
patient looked pale and his conjunctivas were anaemic. His
thyroid gland was enlarged and there were no exophthalmia,
skin rash or edema in lower extremities. Cardiovascular
examination was normal.
Urine analysis showed haematuria (4+) and proteinuria
(2+). Laboratory data at admission showed: hemoglobin
9.4g/dL, serum urea 19.7mmol/L (normal range: 2.5–
7.5mmol/L ), serum creatinine 413µmol/L (normal range:
70–130µmol/L); it was 54µmol/L 8 months before, Pro-
teinuria 1.1g/d, haematuria 8000000 red blood cells/mL,
erythrocyte sedimentation rate 102 at 1 hour. Serum
concentrations of CH50, C3 and C4 were in normal
range. Thyroid function was normal with negative antithy-
roglobulin(anti-TG),antiperoxydase(anti-TPO)antibodies,
and positive antithyrotropin receptor antibodies (TRAb)2 Case Reports in Medicine
(range 40UI/mL). Antinuclear and antiglomerular base-
ment membrane antibodies were negative. An indirect
immunoﬂuorescence test for ANCA was positive, showing
a perinuclear pattern with speciﬁcity antimyeloperoxydase
(MPO). A renal biopsy was performed and revealed pauci-
immuneextracapillaryglomerularnephropathyandnecrotic
vasculitis lesions. Based on these ﬁndings the diagnosis
of rapidly progressive glomerulonephritis associated with
ANCA induced by BTU therapy was strongly suggested.
The drug was therefore discontinued and patient was
treated with pulse of methyl prednisolone (500mg/d for
3 days) followed by oral prednisolone (60mg/d) and
monthly intravenous pulses of cyclophosphamide during
3 months. Renal failure, proteinuria and haematuria sig-
niﬁcantly improved within 2 months. Serum creatinine
level decreased to 84µmol/L and urine analysis revealed
no proteinuria or haematuria. However, P-ANCA remained
positive until 10 months after drug withdrawal. Thyroid
function was kept within normal range using iodine
solution.
3. Discussion
In this paper we reported a new case of BTU-induced
ANCA positive vasculitis resulting in necrotizing glomeru-
lonephritis. To our knowledge only four similar cases, with
Benzylthiouracile, have been reported in literature [5–8].
ANCA vasculitis complicating antithyroid drugs was ﬁrst
reported in 1992 by Stankus and Johnsen in a patient
who developed severe respiratory failure with PTU [3]. In
1993, Dolman et al. reported the detection of ANCA in
serum of six patients who developed vasculitis during PTU
treatment of hyperthyroidism [9]. In these patients renal
function was normal with no proteinuria. The ANCAs are
associated to systemic necrotizing vasculitis. The presenting
symptoms of ATD induced ANCA vasculitis are variable
including renal involvement, arthralgia, fever, skin involve-
ment, respiratory tract involvement, myalgia or scleritis
[4]. Our patient presented with clinical and biological
disturbances related to renal failure with no medical his-
tory of pre-existing renal disease. Symptoms occurred 8
months after the beginning of treatment and there was
no evidence of cutaneous vasculitis. ANCA positivity and
renal biopsy which described pauci-immune extracapillary
glomerular nephropathy concluded to the diagnosis of
BTU induced vasculitis. Crescentic glomerulonephritis with
ANCA positive vasculitis was ﬁrstly reported by Vogt in
1994, in 2 children receiving PTU [10]. Since then, many
cases of ANCA positive vasculitis secondary to ATD have
been described with mainly PTU [11, 12] and other ATD
such as Carbimazole, Thiamazole [13, 14] and recently
Benzylthiouracile [5–8]. Crescentic glomerulonephritis is
histopathologically characterized by extracapillary prolifera-
tionandcrescentformationinthemajorityofglomeruliwith
clinical syndrome of rapid deterioration in renal function
occurring within few weeks or months [15]. Although
immune complex was considered to be a possible cause of
nephritis [15], its mechanism is still unknown. Griswold
reported granular deposit of Immunoglobulin, complement
in glomeruli on immunoﬂuorescence, and concluded that
vasculitis secondary to PTU is an immune complex disease
[16]. Besides, it is known that thyroid antigens have been
implicated in the pathogenesis of glomerulonephritis [17].
However, in our case, there were no signiﬁcant deposit of
immune complex and serum antithyroid antibodies (anti-
TG and anti TPO) were negative. This kind of pauci-
immune nephritis is compatible with ANCA induced rapidly
progressive glomerulonephritis as reported by Kudoh [18].
Graves disease is the most common underlying thyroid
disease. ANCA positive vasculitis has been less frequently
reported in association with toxic multionodular goiter
[19]. Severe adverse eﬀects secondary to ATD such as
agranulocytosis usually occur within weeks after initiation
of therapy [20]. However, ANCA positivity seems to be
correlated to duration of therapy, the risk is particularly
important after 18 months of treatment [21]. The clinical
signiﬁcance of ANCA positivity is still controversial. It has
been reported that 20% of patients with hyperthyroidism
taking PTU were serum ANCA positive during the course
of therapy but a small number of them develop vasculitis
[9, 22]. Dolman demonstrated clearly the role of PTU
in vasculitis in 6 patients with vasculitis disorders which
disappeared with concomitant fall in ANCA titers after
withdrawalofPTU[9].ThepathogenesisofANCAmediated
vasculitis is not well understood. It seems that Thionamide
accumulates in neutrophils [23], binds to MPO inducing
alteration of the cell structure [24] and then initiation
of autoantibody formation. Falsely positive ANCA may be
encountered in some patients without systemic manifes-
tation of vasculitis. This phenomenon is explained by a
cross reaction between antithyroid antibodies (anti-TRAb
or anti-TG) and ANCA [25]. Approximately 90% of cases
of ANCA positive vasculitis have occurred in association
with PTU [4]. Only few cases of vasculitis induced by
BTU have been reported in the literature involving prin-
cipally the kidney and the respiratory tract [6–8]. In fact,
the prevalence of PTU-treated patients is much higher
than other antithyroid medication which is a matter of
preference of each doctor and of availability of drugs. In
Tunisia, all cases of ANCA-positive vasculitis descried to date
were secondary to BTU, which is the main ATD used in
practice.
T r e a t m e n to fA N C Ap o s i t i v ev a s c u l i t i sw i t hr e n a l
involvement is controversial. After withdrawal of ATD,
improvement of renal function was obtained in most
reported cases [26, 27]. In the other cases, corticosteroid
treatment and/or immunosuppressive treatment were given
[28, 29]. Since renal involvement in ANCA positive vasculitis
may be a cause of end-stage renal failure, our patient
was treated with cyclophosphamide and prednisolone in
addition to BTU withdrawal. Renal outcome was favor-
able but ANCA remained positive several months after
withdrawal of BTU. Discontinuing ATD does not always
result in fall in titer or disappearance of circulating
ANCA. High MPO-ANCA titers in remission had still been
observed in a substantial number of patients [30]. This
may be a high risk of relapse implying long-term followup
[31].Case Reports in Medicine 3
4. Conclusion
The association between Benzylthiouracile and ANCA vas-
culitisisnowwelldocumented.Althoughitsrareoccurrence,
attention must be given to systemic symptoms such as
skin lesion, haematuria or proteinuria. The ANCA must be
measured whenconfronted to systemic manifestation during
treatment.
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